标题
Tazemetostat: First Approval
作者
关键词
-
出版物
DRUGS
Volume 80, Issue 5, Pages 513-521
出版商
Springer Science and Business Media LLC
发表日期
2020-03-12
DOI
10.1007/s40265-020-01288-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
- (2020) Franck Morschhauser et al. BLOOD
- Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF V600E by synergistically decreasing global trimethylation of H3K27
- (2020) Hao Fu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB IN COMBINATION WITH TAZEMETOSTAT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B STUDY
- (2019) M.L. Palomba et al. HEMATOLOGICAL ONCOLOGY
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
- (2018) Antoine Italiano et al. LANCET ONCOLOGY
- Enhancer of zeste homolog 2 (EZH2) inhibitors
- (2018) Nitya Gulati et al. LEUKEMIA & LYMPHOMA
- Abstract 808: Opportunity for therapeutic expansion in mantle cell lymphoma: Tazemetostat combination synergy status in preclinical MCL models
- (2018) Tami L. Hood et al. CANCER RESEARCH
- Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
- (2018) Marjorie Glass Zauderer et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging EZH2 Inhibitors and Their Application in Lymphoma
- (2018) Jennifer K. Lue et al. Current Hematologic Malignancy Reports
- 1612PDA phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)
- (2018) R L Jones et al. ANNALS OF ONCOLOGY
- 1611PDA phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)
- (2018) S Stacchiotti et al. ANNALS OF ONCOLOGY
- Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
- (2017) Elayne Chan-Penebre et al. MOLECULAR CANCER THERAPEUTICS
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- INI1-Deficient Tumors
- (2011) Travis J. Hollmann et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now